
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna's positive outlook is driven by its strategic goal of achieving $1.4 to $1.7 billion in cost reductions by 2027, demonstrating a commitment to operational efficiency. Additionally, the company aims to break even by 2028, implying a focus on financial sustainability and potential profitability in the near future. Furthermore, Moderna's ongoing development of 35 mRNA candidates across diverse therapeutic areas highlights its innovative pipeline and capacity for growth, particularly in preventative vaccines.
Bears say
The excerpts highlight that Moderna is currently experiencing significant challenges in the short term related to its respiratory syncytial virus (RSV) and COVID vaccine sales, which may negatively impact its revenue forecasts. Despite having a diverse pipeline with 35 mRNA candidates targeting various therapeutic areas, these material headwinds may hinder immediate financial performance and investor confidence. While there are potential upside risks through increased vaccine revenue, cost management, or mergers and acquisitions, the prevailing conditions suggest a cautious outlook for the company's stock.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares